- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,478GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,478GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,478GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,478GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,478GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,478GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,478GBP
- Report
- July 2026
- 160 Pages
Global
From €3770EUR$4,150USD£3,215GBP
- Report
- July 2026
- 160 Pages
Global
From €3770EUR$4,150USD£3,215GBP
- Report
- August 2024
- 150 Pages
Global
From €3406EUR$3,750USD£2,905GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3406EUR$3,750USD£2,905GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2533EUR$2,789USD£2,160GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2533EUR$2,789USD£2,160GBP
- Report
- June 2025
- 250 Pages
United States
From €2533EUR$2,789USD£2,160GBP
- Report
- June 2025
- 300 Pages
Europe
From €3514EUR$3,869USD£2,997GBP
- Report
- May 2025
- 300 Pages
Global
From €4495EUR$4,949USD£3,834GBP
- Report
- February 2024
- 80 Pages
Europe
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 70 Pages
Germany
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 70 Pages
Italy
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 70 Pages
Oman
From €4315EUR$4,750USD£3,679GBP

Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. It is a member of the Endocrine and Metabolic Disorders Drugs class, which are used to treat a variety of conditions related to hormones and metabolism. Lixisenatide works by stimulating the release of insulin from the pancreas, helping to reduce blood sugar levels. It is typically used in combination with other diabetes medications, such as metformin or sulfonylureas.
Lixisenatide is available in both injectable and oral formulations. The injectable form is administered once daily, while the oral form is taken once weekly. Common side effects of lixisenatide include nausea, diarrhea, and headache. It is important to note that lixisenatide should not be used in patients with type 1 diabetes or diabetic ketoacidosis.
Some companies in the Lixisenatide market include Sanofi, Eli Lilly, and Novo Nordisk. Show Less Read more